Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Simon A. Jones, … , Jürgen Scheller, Stefan Rose-John
Simon A. Jones, … , Jürgen Scheller, Stefan Rose-John
Published September 1, 2011
Citation Information: J Clin Invest. 2011;121(9):3375-3383. https://doi.org/10.1172/JCI57158.
View: Text | PDF
Science in Medicine Article has an altmetric score of 23

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

  • Text
  • PDF
Abstract

The successful treatment of certain autoimmune conditions with the humanized anti–IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Authors

Simon A. Jones, Jürgen Scheller, Stefan Rose-John

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Total
Citations: 7 10 10 29 33 27 21 21 35 24 28 25 29 19 1 1 320
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2012 (19)

Title and authors Publication Year
Leptin and mucosal immunity
NM Mackey-Lawrence, WA Petri
Mucosal Immunology 2012
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases
T Tanaka, T Kishimoto
International journal of biological sciences 2012
Innate Immune Cells in Liver Inflammation
E Liaskou, DV Wilson, YH Oo
Mediators of Inflammation 2012
Cross-Species Functional Analysis of Cancer-Associated Fibroblasts Identifies a Critical Role for CLCF1 and IL-6 in Non–Small Cell Lung Cancer In Vivo
S Vicent, LC Sayles, D Vaka, P Khatri, O Gevaert, R Chen, Y Zheng, AK Gillespie, N Clarke, Y Xu, J Shrager, CD Hoang, S Plevritis, AJ Butte, EA Sweet-Cordero
Cancer research 2012
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?
C Finelli, G Tarantino
World journal of gastroenterology : WJG 2012
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice
J Suthaus, C Stuhlmann-Laeisz, VS Tompkins, TR Rosean, W Klapper, G Tosato, S Janz, J Scheller, S Rose-John
Blood 2012
Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
U Elewa, MD Sanchez-Niño, C Martin-Cleary, B Fernandez-Fernandez, J Egido, A Ortiz
International Urology and Nephrology 2012
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
C Johnson, Y Han, N Hughart, J McCarra, G Alpini, F Meng
Translational gastrointestinal cancer 2012
A designer hyper interleukin 11 (H11) is a biologically active cytokine
H Dams-Kozlowska, K Gryska, E Kwiatkowska-Borowczyk, D Izycki, S Rose-John, A Mackiewicz
BMC Biotechnology 2012
The Stress-Induced Cytokine Interleukin-6 Decreases the Inhibition/Excitation Ratio in the Rat Temporal Cortex via Trans-Signaling
F Garcia-Oscos, H Salgado, S Hall, F Thomas, GE Farmer, J Bermeo, LC Galindo, RD Ramirez, S D'Mello, S Rose-John, M Atzori
Biological Psychiatry 2012
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia
A Bonetto, T Aydogdu, X Jin, Z Zhang, R Zhan, L Puzis, LG Koniaris, TA Zimmers
American journal of physiology. Endocrinology and metabolism 2012
Interleukin-6, a major cytokine in the central nervous system
M Erta, A Quintana, J Hidalgo
International journal of biological sciences 2012
d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers
E Magbanua, T Zivkovic, B Hansen, N Beschorner, C Meyer, I Lorenzen, J Grötzinger, J Hauber, AE Torda, G Mayer, S Rose-John, U Hahn
RNA biology 2012
Protective role of STAT3 in NMDA and glutamate-induced neuronal death: negative regulatory effect of SOCS3
KW Park, SE Nozell, EN Benveniste
PloS one 2012
An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer
C Garbers, B Spudy, S Aparicio-Siegmund, GH Waetzig, J Sommer, C Hölscher, S Rose-John, J Grötzinger, I Lorenzen, J Scheller
The Journal of biological chemistry 2012
Interleukin-6--a key regulator of colorectal cancer development
MJ Waldner, S Foersch, MF Neurath
International journal of biological sciences 2012
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6
S Rose-John
International journal of biological sciences 2012
Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress
M Girotti, JJ Donegan, DA Morilak
Psychoneuroendocrinology 2012
Role of inflammatory cytokines in peripheral nerve injury
Federica Fregnan, Federica Fregnan, Luisa Muratori, Luisa Muratori, Anabel Rodriguez Simões, Maria Giuseppina Giacobini-Robecchi, Stefania Raimondo
Neural Regeneration Research 2012

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 1 X users
Referenced in 40 patents
Referenced in 1 Wikipedia pages
480 readers on Mendeley
1 readers on CiteULike
See more details